QUOTE AND NEWS
SeekingAlpha  Mar 25  Comment 
By William Meyers: A scientific consensus is emerging that the most likely future cure for cancers will be highly specific combinations of immunotherapy and checkpoint inhibitors, tuned to the specific genetics of the individual cancer target....
SeekingAlpha  Mar 4  Comment 
Dendreon Corp. (DNDN) Cowen and Company 34th Annual Health Care Conference Transcript March 4, 2014 11:20 AM ET Executives John Johnson - Chairman and CEO Analysts Presentation Unidentified Analyst Good morning and...
Benzinga  Mar 4  Comment 
Toward the end of trading Tuesday, the Dow traded up 1.38 percent to 16,391.81 while the NASDAQ surged 1.83 percent to 4,355.50. The S&P also rose, gaining 1.46 percent to 1,872.64. Leading and Lagging Sectors In trading on Tuesday,...
SeekingAlpha  Mar 4  Comment 
By Bill Maurer: A couple of weeks ago, I detailed how it was make or break time for biotech Dendreon (DNDN). The company that brings you the prostate cancer treatment Provenge had an upcoming earnings report that would be the start of a critical...
Benzinga  Mar 4  Comment 
Analysts at Bernstein downgraded Dendreon (NASDAQ: DNDN) from “outperform” to “market perform.” The price target for Dendreon has been lowered from $4.30 to $3.30. Dendreon's shares closed at $3.31 yesterday. Goldman Sachs downgraded...
SeekingAlpha  Mar 3  Comment 
Start Time: 09:00 End Time: 10:00 Dendreon Corporation (DNDN) Q4 2013 Earnings Conference Call March 03, 2014, 09:00 AM ET Executives Lindsay Rocco - IR John H. Johnson - Chairman, President and CEO Gregory R. Cox - Interim...
Benzinga  Mar 3  Comment 
Dendreon (NASDAQ: DNDN) - up 19% - Reports Q4 EPS of $(0.17) vs $(0.37) Est; Revenue of $74.80M vs $73.59M Est. Perion Network (NASDAQ: PERI) - up 13.5% - Reports Q4 2013 Revenue of $31.3M, 47% YoY increase. EBITDA increased 56% YoY reaching...
TheStreet.com  Mar 3  Comment 
NEW YORK (TheStreet) -- Dendreon Corporation  was soaring 18.56% to $3.41 on Monday after the biotechnology company reported fourth-quarter earnings that surpassed analysts' expectations. Dendreon reported a loss of 17 cents per share, which...
Benzinga  Mar 3  Comment 
Vimicro International (NASDAQ: VIMC) moved up 19.09% to $3.53 after the company updated its Q4 forecast and issued a Q1 outlook. The company now projects Q4 revenue of $21 to $22 million, versus its earlier forecast of $13.5 to $15.5...
StreetInsider.com  Mar 3  Comment 
Perion Network Ltd. (NASDAQ: PERI) 14.5% HIGHER; reported Q4 EPS of $0.49, versus $0.32 reported last year. Revenue for the quarter came in at $31.3 million, versus $21.4 million reported last year. Mechel OAO (NYSE: MTL) 13% LOWER; tensions over...




 
TOP CONTRIBUTORS

Dendreon Corporation (NYSE:DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), approved by the FDA in 2010, is a therapeutic vaccine developed for the treatment of prostate cancer. Successful late-stage clinical trials yielded very positive results that could turn Provenge into a blockbuster therapy. Dendreon is beginning to market Provenge in the U.S. on its own.

Dendreon's success over the next few years will depend both on its ability to expand capacity to keep up with demand for the drug as well as overall success of Provenge in the advanced prostate cancer market.

Business Growth

FY 2010 (ended December 31, 2010

  • Net revenue surpassed $1 million for the first time at $48 million.[1]
  • Revenue forecast for 2011 is$350 to 400 million.[2]

In 2010, Dendreon achieved FDA approval for its flagship therapy, Provenge, to treat advanced prostate cancer.[3] Revenue from sales of Provenge drove Dendreon's revenue increase in 2010, and will continue to drive Dendreon's revenue as it continues to build market share. Dendreon has yet to post a profit, and operational expenses to develop, manufacture, and market Provenge tripled to $300 million in 2010. Thomson Reuters projects an earnings loss again in 2011, but sees Dendreon becoming profitable in 2012.[4]

Pipeline

Provenge treats cancer as an active cellular immunotherapy (ACI), getting the patient's immune system to selectively attack cancer cells. Dendreon is developing the Provenge compound (Sepuleucel-T) as well as other ACI compounds for several cancer types[5]:

  • Sepuleucel-T: Dendreon currently has Sepuleucel-T, the compound behind Provenge, in Phase 2 and 3 trials for both early and advance stage Prostate cancer.
  • ACI Therapy for Breast Cancer: Dendron has a therapy that targets the Her2 receptor common in certain forms of breast cancer currently in Phase 1 trials.

Trends and Forces

Sales Growth for Provenge Will Drive Dendreon's Future Revenue

Over the next few years, virtually all of Dendreon's revenue will come from sales of its cancer drug, Provenge. Analysts predict that Provenge sales will peak at $2-3 billion, with sales in 2012 of $800 million.[6] However, the sales numbers that Dendreon is actually able to realize depend on a few factors. First, as the first cancer treatment of its kind, demand for Provenge may be difficult to predict. Second, Provenge costs $93,000 for 4 months of life extension in cancer patients, a cost that some doctors may balk at.[7] Dendreon's valuation over the next few years will be inextricably tied to the performance of Provenge.

Dendreon's Ability to Keep Up with Provenge Demand will Affect Revenue

The process of manufacturing Provenge is relatively complex, requiring treatments personalized for each patient, and Dendron may have trouble keeping up with demand. Early on, the company has seen production constraints dampen sales.[8][9] While Dendreon has added three manufacturing plants to its arsenal in order to meet demand,[10] the complexities inherent to the manufacturing process make manufacturing capacity an important indicator for Provenge's short-term sales.

Competition

Sanofi-Aventis SA (SNY): Sanofi Aventis received FDA approval for it new drug, Jevtana, to treat patients with advanced prostate cancer. Jevtana will compete with Provenge for patients, although the demand backlog for Provenge while Dendreon ramps up its capacity, will make up for any sales losses from competition.[11]

JOHNSON & JOHNSON (JNJ): Zytiga received FDA approval for advanced prostate cancer and will compete along with Provenge and Jevtana for market share.[12]

References

  1. DNDN 2011 10K
  2. BiotechSectorInvesting DNDN Earnings
  3. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer
  4. Ahead of Earnings: Analysts Fight Over Dendreon (DNDN)
  5. Dendreon R&D
  6. Dendreon: Make or Break Year for Provenge
  7. Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?
  8. Dendreon's Biggest Provenge Problem? Managing Demand
  9. Dendreon sees Provenge contraints over by year end
  10. Dendreon boosts Provenge production, treatment sites
  11. New Dendreon Competition Is Not Really Competition (DNDN, SNY)
  12. Abiraterone in Prostate Cancer, Survival Gets Even Better
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki